Cromolyn in extrinsic and intrinsic asthma

Abstract

Cromolyn sodium was evaluated in 30 patients with intrinsic bronchial asthma and in 29 patients with extrinsic bronchial asthma using a double-blind crossover method. Each patient was studied during a base line, placebo, and cromolyn period. Daily evaluation was performed with regard to upper respiratory tract symptoms, lower respiratory tract symptoms, oral medication scores, use of sympathomimetic agents by aerosolization and peak expiratory flow rates measured 5 times a day. Weekly evaluation consisted of a physician's evaluation and a timed vital capacity. At the end of each test period spirometry, airway resistance and an exercise tolerance test were performed. Evaluation of the intrinsic asthmatic patients revealed significant improvement during the cromolyn period as compared to the placebo and base line periods with regard to the daily recorded variables and the physician's evaluation. Study of the other parameters showed no significant trend. Evaluation of the use of cromolyn in extrinsic bronchial asthma revealed no general trends for any of the parameters measured.